Blog

The transformative odyssey of Tumour Agnostic Drug Development in Precision Medicine – ESMO

Vivek Subbiah/LinkedIn

Mar 5, 2025, 07:35

The transformative odyssey of Tumour Agnostic Drug Development in Precision Medicine – ESMO

ESMO (European Society for Medical Oncology) shared a post on LinkedIn:

“ESMOTAT25: The transformative odyssey of Tumour Agnostic Drug Development in Precision Medicine.

Vivek Subbiah, MD discusses the paradigm shift away, at least partially, from organ-based treatment to molecularly guided treatment across tumour types. He describes how regulatory shifts and greater access to tumour profiling are now needed to realise their full benefits for patients.

To learn more, read the Opinion piece in the ESMO Daily Reporter.”

The transformative odyssey of Tumour Agnostic Drug Development in Precision Medicine - ESMO

More posts featuring ESMO.

cancer ESMO ESMO Daily Reporter ESMOTAT25 European Society for Medical Oncology OncoDaily Oncology Precision Medicine Tumour Agnostic Drug Development Vivek Subbiah

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers